Vista Pharmaceuticals (524711) Q2 25/26 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half year ended 30 September 2025, along with the limited review report by statutory auditors.

• Financial statements prepared in accordance with Indian Accounting Standards (Ind AS).

Financial highlights

• Total revenue for Q2 FY26 was ₹165.49 lakhs, down from ₹250.17 lakhs in Q2 FY25.

• Loss before tax for Q2 FY26 was ₹362.21 lakhs, compared to a loss of ₹125.20 lakhs in Q2 FY25.

• Net loss for Q2 FY26 stood at ₹258.85 lakhs, versus ₹129.04 lakhs in Q1 FY26 and ₹97.37 lakhs in Q2 FY25.

• Basic EPS for Q2 FY26 was (₹0.42), compared to (₹0.16) in Q2 FY25.

Outlook and guidance

• Management recognized a provision for expected credit loss (ECL) of ₹205.43 lakhs in Q2 FY26, reflecting a cautious outlook on long-pending trade receivables.